Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
45 participants
OBSERVATIONAL
2024-12-08
2038-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
NCT05577312
Long-term Follow-up Study of BHC001 for TDT
NCT06314529
A Long-term Follow-up Study in Participants Who Received CS-101
NCT06685536
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
NCT06717932
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
NCT03351829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BRL-101
All patients who have received BRL-101
Assessments
Safety and efficacy assessments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assessments
Safety and efficacy assessments
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
3 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Guangxi Medical University
OTHER
Xiangya Hospital of Central South University
OTHER
Chinese Academy of Medical Sciences
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
OTHER
Shenzhen Children 's Hospital
UNKNOWN
Bioray Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaochen Wang
Role: STUDY_CHAIR
Bioray Laboratories
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Shenzhen Children 's Hospital
Shenzhen, Guangdong, China
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
Nanning, Guangxi, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Tianjin Institute of Hematology
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
Guangxi, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaoqin Feng, phD
Role: primary
Jianpei Fang, phD
Role: primary
Sixi Liu, phD
Role: primary
Xinhua Zhang, phD
Role: primary
Bin Fu, PhD
Role: primary
Jun shi, PhD
Role: primary
Yongrong Lai, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-LTF-BRL-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.